Abbisko Cayman (2256) Stock Overview
Engages in the research, discovery, and development of pharmaceutical products in Mainland China and the European Union. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
2256 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Abbisko Cayman Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$9.52 |
| 52 Week High | HK$19.78 |
| 52 Week Low | HK$8.90 |
| Beta | 1.26 |
| 1 Month Change | -26.32% |
| 3 Month Change | -14.62% |
| 1 Year Change | 0.32% |
| 3 Year Change | 242.45% |
| 5 Year Change | n/a |
| Change since IPO | -23.23% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2256 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -7.0% | -2.5% | -1.6% |
| 1Y | 0.3% | 21.3% | 10.4% |
Return vs Industry: 2256 underperformed the Hong Kong Biotechs industry which returned 21.3% over the past year.
Return vs Market: 2256 underperformed the Hong Kong Market which returned 10.4% over the past year.
Price Volatility
| 2256 volatility | |
|---|---|
| 2256 Average Weekly Movement | 7.4% |
| Biotechs Industry Average Movement | 8.7% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in HK Market | 15.6% |
| 10% least volatile stocks in HK Market | 3.6% |
Stable Share Price: 2256 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2256's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 276 | Yao-Chang Xu | www.abbisko.com |
Abbisko Cayman Limited, together with its subsidiaries, engages in the research, discovery, and development of pharmaceutical products in Mainland China and the European Union. The company develops Pimicotinib (ABSK021), a small molecule CSF-1R inhibitor, which is in NDA/commercial stage for the treatment of tenosynovial giant cell tumors and Phase Ib/II for the treatment of chronic graft versus host disease; and Irpagratinib (ABSK011), a small-molecule inhibitor of FGFR4, which is in pivotal stage and Phase Ib/II for the treatment of hepatocellular carcinoma. It also engages in the development of ABSK061, which is in Phase Ib/II for the treatment of gastric cancer and achondroplasia; and ABSK043, which is in Phase Ib/II for the treatment of solid tumors and non-small cell lung cancer.
Abbisko Cayman Limited Fundamentals Summary
| 2256 fundamental statistics | |
|---|---|
| Market cap | HK$6.82b |
| Earnings (TTM) | HK$64.00m |
| Revenue (TTM) | HK$709.10m |
Is 2256 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2256 income statement (TTM) | |
|---|---|
| Revenue | CN¥612.12m |
| Cost of Revenue | CN¥0 |
| Gross Profit | CN¥612.12m |
| Other Expenses | CN¥556.87m |
| Earnings | CN¥55.25m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.077 |
| Gross Margin | 100.00% |
| Net Profit Margin | 9.03% |
| Debt/Equity Ratio | 15.2% |
How did 2256 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/01 00:33 |
| End of Day Share Price | 2026/06/01 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Abbisko Cayman Limited is covered by 19 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | China International Capital Corporation Limited |
| Jin Zhang | China International Capital Corporation Limited |
| Ziyu He | China International Capital Corporation Limited |